HomeCompareAGNMF vs ABBV

AGNMF vs ABBV: Dividend Comparison 2026

AGNMF yields 2259.89% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGNMF wins by $31152221668.38M in total portfolio value
10 years
AGNMF
AGNMF
● Live price
2259.89%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31152221668.48M
Annual income
$28,657,673,035,409,468.00
Full AGNMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AGNMF vs ABBV

📍 AGNMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGNMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGNMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGNMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGNMF
Annual income on $10K today (after 15% tax)
$192,090.40/yr
After 10yr DRIP, annual income (after tax)
$24,359,022,080,098,050.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AGNMF beats the other by $24,359,022,080,076,990.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGNMF + ABBV for your $10,000?

AGNMF: 50%ABBV: 50%
100% ABBV50/50100% AGNMF
Portfolio after 10yr
$15576110834.29M
Annual income
$14,328,836,517,717,120.00/yr
Blended yield
91.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AGNMF
No analyst data
Altman Z
173.1
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGNMF buys
0
ABBV buys
0
No recent congressional trades found for AGNMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGNMFABBV
Forward yield2259.89%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$31152221668.48M$102.3K
Annual income after 10y$28,657,673,035,409,468.00$24,771.77
Total dividends collected$30976745118.31M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AGNMF vs ABBV ($10,000, DRIP)

YearAGNMF PortfolioAGNMF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$236,689$225,988.70$11,550$430.00+$225.1KAGNMF
2$5,252,226$4,998,969.33$13,472$627.96+$5.24MAGNMF
3$109,292,149$103,672,266.92$15,906$926.08+$109.28MAGNMF
4$2,133,099,643$2,016,157,043.87$19,071$1,382.55+$2133.08MAGNMF
5$39,058,269,832$36,775,853,213.45$23,302$2,095.81+$39058.25MAGNMF
6$671,125,830,858$629,333,482,137.96$29,150$3,237.93+$671125.80MAGNMF
7$10,824,307,545,111$10,106,202,906,092.71$37,536$5,121.41+$10824307.51MAGNMF
8$163,917,257,204,277$152,335,248,131,008.78$50,079$8,338.38+$163917257.15MAGNMF
9$2,331,353,862,682,441$2,155,962,397,473,863.80$69,753$14,065.80+$2331353862.61MAGNMF
10$31,152,221,668,479,684$28,657,673,035,409,468.00$102,337$24,771.77+$31152221668.38MAGNMF

AGNMF vs ABBV: Complete Analysis 2026

AGNMFStock

Agronomics Limited is a principal investment firm specializing in investments in funds, equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on cellular agriculture, nascent industry of modern foods, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Agronomics Limited was founded on May 3, 2011 and is based in Ramsey, Isle of Man.

Full AGNMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AGNMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGNMF vs SCHDAGNMF vs JEPIAGNMF vs OAGNMF vs KOAGNMF vs MAINAGNMF vs JNJAGNMF vs MRKAGNMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.